Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MELSX | 16.47 | 0.12 | +0.73% |
| Morgan Stanley Inst EMkts Ldrs R6 | |||
| JLFSX | 12.43 | 0.09 | +0.73% |
| JHancock Global Climate Action I | |||
| DMIDX | 28.82 | 0.18 | +0.63% |
| BNY Mellon MidCap Index I | |||
| ARTIX | 34.17 | 0.10 | +0.29% |
| Artisan International Investor | |||
| FCENX | 13.85 | 0.01 | +0.07% |
| Franklin International Core Equity Adv | |||
A.I.dvisor indicates that over the last year, HNSBF has been loosely correlated with ENSC. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HNSBF jumps, then ENSC could also see price increases.
| Ticker / NAME | Correlation To HNSBF | 1D Price Change % | ||
|---|---|---|---|---|
| HNSBF | 100% | N/A | ||
| ENSC - HNSBF | 33% Loosely correlated | +1.76% | ||
| CVAC - HNSBF | 33% Poorly correlated | +0.93% | ||
| MLLCF - HNSBF | 27% Poorly correlated | N/A | ||
| GNPX - HNSBF | 25% Poorly correlated | -3.59% | ||
| GRI - HNSBF | 25% Poorly correlated | -0.69% | ||
More | ||||